BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Labetalol

A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.

295+ PubMed studies analyzed · 63 RCTs · Evidence Score: 55.9

Research Domains

Labetalol has been studied across 15 research domains including ❤️ Cardiovascular, 🫘 Kidney, 🧠 Focus & Attention, 😴 Sleep, 🔬 Oncology. The primary research focus is ❤️ Cardiovascular with 72% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Labetalol, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Propranolol
14 shared targets
Sotalol
9 shared targets
Lisuride
13 shared targets
Timolol
8 shared targets
Atenolol
8 shared targets
Levobunolol
6 shared targets
Dihydroergotamine
15 shared targets
Clenbuterol
7 shared targets
Cinnarizine
14 shared targets
Trazodone
11 shared targets
Loading evidence profile...

This evidence profile for Labetalol is generated deterministically from 295 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.